Phaseline

Targets › SIRT6

SIRT6 (NAD-dependent protein deacylase sirtuin-6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology.

NAD-dependent protein deacetylase, deacylase and mono-ADP-ribosyltransferase that plays an essential role in DNA damage repair, telomere maintenance, metabolic homeostasis, inflammation, tumorigenesis and aging. Displays protein-lysine deacetylase or defatty-acylase (demyristoylase and depalmitoylase) activity, depending on the context. (UniProt, Q8N6T7)

Open in Phaseline: the race on SIRT6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tisento Therapeuticszagociguat
Sirtuin 6 (SIRT6) activator
SIRT6Phase 2Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)–

Conditions

Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome) (1)

Modalities

small molecule (1)

Companies

Tisento Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.